兆新股份(002256.SZ)股東陳永弟所持約4.94億股新增輪候凍結
格隆匯11月15日丨兆新股份(002256.SZ)公佈,公司於2019年11月14日通過中國證券登記結算有限責任公司深圳分公司系統查詢,獲悉公司股東陳永弟所持有的公司股份新增輪候凍結,合計輪候凍結約4.94億股,佔其所持有股份比例100.00%。
截至2019年11月14日,陳永弟共持有公司股份約4.94億股,佔公司總股本的26.26%;累計被質押股數為約4.94億股,佔公司總股本的26.24%,佔其持有公司股份總數的99.92%;累計被司法凍結股數為約4.94億股,佔其持有公司股份總數的100.00%;累計被輪候凍結數為約34.9億股,佔其持有公司股份總數的705.99%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.